Edgewise Therapeutics, Inc.

Biotechnology • Healthcare • Boulder, CO, United States • EWTX (NMS)

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.

720 262 7002 1715 38th Street, Boulder, CO 80301, United States

Stock Performance (90 Days)

Data through Dec 26, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - PR Newswire

PR Newswire • Jan 5

Why Edgewise Therapeutics Stock Rocked the Market Today - The Motley Fool

The Motley Fool • Dec 24

Edgewise Therapeutics (EWTX): Assessing Valuation After an 80% Three-Month Surge in the Share Price - Yahoo Finance

Yahoo Finance • Dec 25

Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: Exploring a 61.93% Upside Potential in Biotech - DirectorsTalk Interviews

DirectorsTalk Interviews • Jan 6

A Look At Edgewise Therapeutics (EWTX) Valuation After Positive CIRRUS HCM Phase 2 Trial Update - simplywall.st

simplywall.st • Jan 6

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Edgewise Therapeutics, Inc. had layoffs?

No layoff events have been recorded for Edgewise Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Edgewise Therapeutics, Inc. have?

Edgewise Therapeutics, Inc. has approximately 136 employees.

What industry is Edgewise Therapeutics, Inc. in?

Edgewise Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Edgewise Therapeutics, Inc. a publicly traded company?

Yes, Edgewise Therapeutics, Inc. is publicly traded under the ticker symbol EWTX on the NMS. The company has a market capitalization of approximately $2.79 billion.

Where is Edgewise Therapeutics, Inc. headquartered?

Edgewise Therapeutics, Inc. is headquartered in Boulder, CO, United States at 1715 38th Street, Boulder, CO 80301, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.